Singapore has quickly become a regional leader in digital health innovation thanks to its strong regulatory frameworks for emerging technologies, including mobile health applications, connected wearables, and AI-enabled devices. As healthcare delivery increasingly makes the transition to digital platforms over the years, the Singaporean Health Sciences Authority (HSA) has established a robust set of guidelines and pathways that protect patients while promoting innovation.

HSA Definition of Digital Health

The HSA defines digital health as a broad category of technology-enabled products, including telehealth and telemedicine, mobile health apps, connected wearables, personalized medicine, and health information technologies. These products use connected devices, software, and AI to facilitate clinical needs through information and communications technologies.

A Framework Supporting Digital Health Innovation

Singapore has introduced various initiatives to assist innovators in understanding regulatory expectations and accelerate patient access to safe, effective digital health products.

1. Regulatory Guidelines for Telehealth Products (2017)

HSA’s telehealth guidance supports manufacturers, developers, and importers in determining whether their digital health tool aligns with the medical device definition. The telehealth guidelines explain the regulatory requirements to ensure telehealth products are safe and of good quality.

2. Immediate Registration Pathway for Standalone Software and Mobile Apps (2018)

Recognizing the rapid iteration cycle of software, the HSA established an immediate registration pathway that utilizes approvals from trusted reference regulators from Australia, Canada, the EU, Japan, and the United States. Products that align with the HSA’s criteria may enter the market immediately, while the HSA simultaneously verifies the safety, effectiveness, and eligibility of these products.

3. Device Development Consultation Scheme

The HSA works directly with researchers, manufacturers, and developers under the Device Development Consultation Scheme to clarify regulatory pathways early in the product lifecycle. Digital health solutions represent over 40% of these consultations, demonstrating significant industry demand for consultations regarding complex issues that arise from software-based technologies.

4. Regulatory Guidelines for Software Medical Devices (April 2020)

With increasing awareness of the importance of cybersecurity, data integrity, and secure software lifecycle management, the HSA has published guidelines to bring together the regulatory standards for software in medical devices. These guidelines function as a central reference for developers to address risk from the point of development to post-market use.

5. AI in Healthcare Guidelines (2021)

With the increasing prominence of AI in Singapore’s healthcare industry, the Ministry of Health (MOH), Integrated Health Information Systems (IHiS), and the HSA collaborated to develop guidance to support the safe development and use of AI-powered medical devices (AI-MDs). These guidelines clarify HSA’s expectations with respect to algorithm design, validation, transparency, and monitoring post-deployment.

6. Clinical Trials for Machine Learning–Enabled Medical Devices (MLMD)

The Ministry of Food and Drug Safety (MFDS) of Korea and Singapore together issued principles for clinical studies regarding MLMD. Specifically, these principles tackle challenges unique to machine learning models, including the model training, testing, and adaptation processes. By establishing shared standards, the collaboration plans to support rigorous assessments of MLMD safety and performance.

Determining Whether a Digital Health Product Is a Medical Device

In Singapore, a digital health product is classified as a medical device if it serves the purpose of investigating, detecting, diagnosing, monitoring, treating, or managing a medical condition, disease, anatomy, or physiological process.

Examples of digital health products include diagnostic applications, artificial intelligence support for image interpretation and imaging solutions, wearable monitors that track vital markers, and connected devices that provide therapeutic applications.

If the product meets the definition outlined above, it will be subject to regulatory oversight by HSA, including:

• Registration for products under regulation by HSA
• Quality management systems
• Good distribution practice
• Post-market requirements, including the reporting of adverse events and vigilance

Ensuring Safety Through Lifecycle Oversight

Digital health technologies are subject to rapid evolution and change, often through software updates or changing cybersecurity threats. The HSA clearly states that Singapore’s regulatory framework is designed to remain “relevant and fit for purpose” as the ecosystem of digital health expands. Post-market surveillance is essential. The HSA monitors real-world outcomes and risks, especially in relation to cybersecurity, and takes action to ensure that patients remain safe wherever necessary.

Conclusion

Singapore’s regulatory approach provides a balance between enabling innovation and maintaining appropriate safety mechanisms that provide a space for the use of digital health technologies, while also maintaining confidence from healthcare professionals and patients. With dedicated pathways and regulatory guidelines and strong international collaborations with other health authorities, this continues to position Singapore as a leading center to develop digital health in Asia.

---

Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.